Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Bank of New York Mellon Corp Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)
09:08am, Tuesday, 07'th Apr 2020
Bank of New York Mellon Corp acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 134,117 shares of the biotechnology
Homology Medicines (FIXX) Gets a Buy Rating from Canaccord Genuity
10:04am, Monday, 06'th Apr 2020
In a report released today, Michelle Gilson from Canaccord Genuity reiterated a Buy rating on Homology Medicines (FIXX), with a price target of $37.00.
Homology Medicines (FIXX) Gets a Buy Rating from Canaccord Genuity
10:04am, Monday, 06'th Apr 2020
In a report released today,
Michelle Gilson
from Canaccord Genuity reiterated a
Buy
rating on Homology Medicines (
FIXX
–
Research Report
), with a price target of
$37.00
. The company’s shares cl
Canaccord Genuity Keeps Their Buy Rating on Homology Medicines (FIXX)
10:04am, Monday, 06'th Apr 2020
Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on Homology Medicines (FIXX) on April 3 and set a price target of $37.00. The company's
Canaccord Genuity Keeps Their Buy Rating on Homology Medicines (FIXX)
10:04am, Monday, 06'th Apr 2020
Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on Homology Medicines (FIXX – Research Report) on April 3 and
Ascendis Pharma A/S Expected to Post FY2023 Earnings of $0.36 Per Share (NASDAQ:ASND)
06:54am, Monday, 06'th Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) – Research analysts at Oppenheimer boosted their FY2023 earnings per share estimates for shares of Ascendis Pharma A/S in a report released on Thursday, April 2nd.
Franklin Resources Inc. Sells 59,492 Shares of Ascendis Pharma A/S (NASDAQ:ASND)
10:26am, Saturday, 04'th Apr 2020
Franklin Resources Inc. lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 6.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 818,742 shares of the biotechnol
Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Lowered by Zacks Investment Research
07:26am, Saturday, 04'th Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to
Wedbush Maintains a Buy Rating on Ascendis Pharma (ASND)
10:25pm, Thursday, 02'nd Apr 2020
Wedbush analyst Liana Moussatos maintained a Buy rating on Ascendis Pharma (ASND) today and set a price target of $186.00. The company's shares closed
Wedbush Maintains a Buy Rating on Ascendis Pharma (ASND)
10:25pm, Thursday, 02'nd Apr 2020
Wedbush analyst Liana Moussatos maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price
Analysts Offer Insights on Healthcare Companies: Arena Pharma (ARNA) and Ascendis Pharma (ASND)
06:44pm, Thursday, 02'nd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arena Pharma (ARNA) and Ascendis Pharma (ASND) with bullish
Analysts Offer Insights on Healthcare Companies: Arena Pharma (NASDAQ: ARNA) and Ascendis Pharma (NASDAQ: ASND)
06:44pm, Thursday, 02'nd Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arena Pharma
Wall Street Analysts Are Bullish on Top Healthcare Picks
05:06pm, Thursday, 02'nd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY), Ascendis Pharma (ASND) and
Edited Transcript of ASND earnings conference call or presentation 1-Apr-20 8:30pm GMT
01:44pm, Thursday, 02'nd Apr 2020
Q4 2019 Ascendis Pharma A/S Earnings Call
Analysts' Top Healthcare Picks: Hologic (HOLX), Ascendis Pharma (ASND)
09:44am, Thursday, 02'nd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hologic (HOLX) and Ascendis Pharma (ASND) with bullish
